Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for myocardial infarction
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on myocardial infarction or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on myocardial infarction and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Traditional risk factors may not explain increased incidence of myocardialinfarction in MS To compare the risk of incident acute myocardialinfarction (AMI) in the multiple sclerosis (MS) population and a matched population without MS, controlling for traditional vascular risk factors.We conducted a retrospective matched cohort study using population-based administrative (health claims) data in 2 Canadian provinces, British Columbia and Manitoba. We identified incident MS cases using
Association of genetically predicted testosterone with thromboembolism, heart failure, and myocardialinfarction: mendelian randomisation study in UK Biobank. To determine whether endogenous testosterone has a causal role in thromboembolism, heart failure, and myocardial infarction.Two sample mendelian randomisation study using genetic variants as instrumental variables, randomly allocated at conception, to infer causality as additional randomised evidence.Reduction by Dutasteride of Prostate (...) Cancer Events (REDUCE) randomised controlled trial, UK Biobank, and CARDIoGRAMplusC4D 1000 Genomes based genome wide association study.3225 men of European ancestry aged 50-75 in REDUCE; 392 038 white British men and women aged 40-69 from the UK Biobank; and 171 875 participants of about 77% European descent, from CARDIoGRAMplusC4D 1000 Genomes based study for validation.Thromboembolism, heart failure, and myocardialinfarction based on self reports, hospital episodes, and death.Of the UK Biobank
Long-Term Effects of Oxygen Therapy on Death or Hospitalization for Heart Failure in Patients With Suspected Acute MyocardialInfarction In the DETO2X-AMI trial (Determination of the Role
of Oxygen in Suspected Acute MyocardialInfarction), we compared
supplemental oxygen with ambient air in normoxemic patients presenting
with suspected myocardialinfarction and found no significant survival
benefit at 1 year. However, important secondary end points were
not yet available. We now report (...) the prespecified secondary end
points cardiovascular death and the composite of all-cause death and
hospitalization for heart failure.In this pragmatic, registry-based randomized clinical trial, we
used a nationwide quality registry for coronary care for trial procedures
and evaluated end points through the Swedish population registry
(mortality), the Swedish inpatient registry (heart failure), and cause of
death registry (cardiovascular death). Patients with suspected acute
myocardialinfarction and oxygen
Mild Hypothermia in Cardiogenic Shock Complicating MyocardialInfarction Experimental trials suggest improved outcome by mild therapeutic hypothermia for cardiogenic shock after acute myocardialinfarction. The objective of this study was to investigate the hemodynamic effects of mild therapeutic hypothermia in patients with cardiogenic shock complicating acute myocardial infarction.Patients (n=40) with cardiogenic shock undergoing primary percutaneous coronary intervention without classic (...) hypothermia failed to show a substantial beneficial effect on cardiac power index at 24 hours in patients with cardiogenic shock after acute myocardial infarction.URL: https://www.clinicaltrials.gov . Unique identifier: NCT01890317.
Evaluation of Microvascular Injury in Revascularized Patients With ST-Segment-Elevation MyocardialInfarction Treated With Ticagrelor Versus Prasugrel Despite successful restoration of epicardial vessel patency with primary percutaneous coronary intervention, coronary microvascular injury occurs in a large proportion of patients with ST-segment-elevation myocardialinfarction, adversely affecting clinical and functional outcome. Ticagrelor has been reported to increase plasma adenosine levels (...) , which might have a protective effect on the microcirculation. We investigated whether ticagrelor maintenance therapy after revascularized ST-segment-elevation myocardialinfarction is associated with less coronary microvascular injury compared to prasugrel maintenance therapy.A total of 110 patients with ST-segment-elevation myocardialinfarction received a loading dose of ticagrelor and were randomized to maintenance therapy of ticagrelor (n=56) or prasugrel (n=54) after primary percutaneous
Usefulness of Triiodothyronine Replacement Therapy in Patients With ST Elevation MyocardialInfarction and Borderline/Reduced Triiodothyronine Levels (from the THIRST Study) The aim of the study was to investigate whether TH replacement therapy is safe and impact infarct size, left ventricular (LV) volumes and function in patients with acute myocardialinfarction (AMI) and low T3 syndrome (LT3S). Thirty-seven AMI/LT3S patients were randomly treated or untreated with liothyronine (T3) therapy (...) (maximum dosage 15 mcg/m2/die) in addition to standardized treatment (T3-treated group, n = 19; untreated group, n = 18). TH and thyroxine (TSH) during hospital stay and at 1-month and 6 months were evaluated. At discharge and at 6 months LV volumes, ejection fraction, wall motion score index (WMSI) and infarct extent were measured by cardiac MR. T3-treated patients had a significant increase in fT3 (p = 0.003 and p <0.001) at discharge and 1-month. These patients had no signs or symptoms
Revised Cardiac Risk Index as a Predictor for MyocardialInfarction and Cardiac Arrest Following Posterior Lumbar Decompression A retrospective analysis of prospectively collected data.The aim of this study was to determine the ability of Revised Cardiac Risk Index (RCRI) to predict adverse cardiac events following posterior lumbar decompression (PLD).PLD is an increasingly common procedure used to treat a variety of degenerative spinal conditions. The RCRI is used to predict risk for cardiac (...) complications.Membership in the RCRI=1 cohort was a predictor for myocardialinfarction (MI) [odds ratio (OR) = 3.3, P = 0.002] and cardiac arrest requiring cardiopulmonary resuscitation (CPR) (OR = 3.4, P = 0.013). Membership in the RCRI = 2 cohort was a predictor for MI (OR = 5.9, P = 0.001) and cardiac arrest requiring CPR (OR = 12.5), Membership in the RCRI = 3 cohort was a predictor for MI (OR = 24.9) and cardiac arrest requiring CPR (OR = 26.9, P = 0.006). RCRI had a good discriminative ability to predict both
Unloading the Left Ventricle Before Reperfusion in Patients With Anterior ST-Segment-Elevation MyocardialInfarction In ST-segment-elevation myocardialinfarction (STEMI), infarct size correlates directly with heart failure and mortality. Preclinical testing has shown that, in comparison with reperfusion alone, mechanically unloading the left ventricle (LV) before reperfusion reduces infarct size and that 30 minutes of unloading activates a cardioprotective program that limits reperfusion (...) ). The primary safety outcome was a composite of major adverse cardiovascular and cerebrovascular events at 30 days. Efficacy parameters included the assessment of infarct size by using cardiac magnetic resonance imaging.All patients completed the U-IR (n=25) or U-DR (n=25) protocols with respective mean door-to-balloon times of 72 versus 97 minutes. Major adverse cardiovascular and cerebrovascular event rates were not statistically different between the U-IR versus U-DR groups (8% versus 12%, respectively
Risk Estimation in Type 2 MyocardialInfarction and Myocardial Injury: The TARRACO Risk Score. Despite adverse prognoses of type 2 myocardialinfarction and myocardial injury, an effective, practical risk stratification method remains an unmet clinical need. We sought to develop an efficient clinical bedside tool for estimating the risk of major adverse cardiovascular events at 180 days for this patient population.The derivation cohort included patients with type 2 myocardialinfarction (...) or myocardial injury admitted to a tertiary hospital between 2012 and 2013 (n = 611). The primary outcome was a major adverse cardiovascular event (death or readmission for heart failure or myocardialinfarction). The score included clinical variables significantly associated with the outcome. External validation was conducted using the UTROPIA cohort (n = 401).The TARRACO Score included cardiac troponin (cTn) concentrations and 5 independent clinical predictors of adverse cardiovascular events: age
Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardialinfarction: the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in MyocardialInfarction (IS Bioresorbable scaffolds (BRS) provide short-term coronary artery scaffolding and drug delivery. Although prior trials showed a higher rate of device failure compared with conventional drug-eluting stents (DES), only a single trial investigated (...) patients undergoing percutaneous coronary intervention (PCI) for acute myocardialinfarction (MI). We aimed to compare outcomes with BRS vs. DES in patients undergoing PCI for MI.We did a prospective, randomized, multicentre, non-inferiority, clinical trial of everolimus-eluting BRS vs. durable polymer everolimus-eluting stents (EES) in patients with acute MI. Patients were eligible for enrolment if they presented with ST-elevation MI, or non-ST-elevation MI with thrombosis visual at angiography
Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With MyocardialInfarction: The ARTEMIS Randomized Clinical Trial. Despite guideline recommendations, many patients discontinue P2Y12 inhibitor therapy earlier than the recommended 1 year after myocardialinfarction (MI), and higher-potency P2Y12 inhibitors are underutilized. Cost is frequently cited as an explanation for both of these observations.To determine whether removing
Effect of Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention on Microvascular Obstruction in Patients With Acute MyocardialInfarction: A Randomized Clinical Trial. Microvascular obstruction commonly affects patients with acute ST-segment elevation myocardialinfarction (STEMI) and is associated with adverse outcomes.To determine whether a therapeutic strategy involving low-dose intracoronary fibrinolytic therapy with alteplase infused early after coronary (...) infusion over 5 to 10 minutes. The intervention was scheduled to occur early during the primary PCI procedure, after reperfusion of the infarct-related coronary artery and before stent implant.The primary outcome was the amount of microvascular obstruction (% left ventricular mass) demonstrated by contrast-enhanced cardiac magnetic resonance imaging (MRI) conducted from days 2 through 7 after enrollment. The primary comparison was the alteplase 20-mg group vs the placebo group; if not significant
Platelet inhibition with standard versus lower maintenance dose of ticagrelor early after myocardialinfarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study. Currently available data indicate that reduction of ticagrelor maintenance dose (MD) 1-3 years after acute myocardialinfarction (AMI) not only provides sufficient platelet inhibition, but also can improve ticagrelor's safety profile. The aim of this study was to compare the antiplatelet
Intraaortic Balloon Pump in Cardiogenic Shock Complicating Acute MyocardialInfarction: Long-Term 6-Year Outcome of the Randomized IABP-SHOCK II Trial The role of intraaortic balloon counterpulsation (IABP) in cardiogenic shock is still a subject of intense debate despite the neutral results of the IABP-SHOCK II trial (Intraaortic Balloon Pump in Cardiogenic Shock II) with subsequent downgrading in international guidelines. So far, randomized data on the impact of IABP on long-term clinical (...) outcomes in patients with cardiogenic shock complicating acute myocardialinfarction are lacking. Furthermore, only limited evidence is available on general long-term outcomes of patients with cardiogenic shock treated by contemporary practice.The IABP-SHOCK II trial is a multicenter, randomized, openlabel trial. Between 2009 and 2012, 600 patients with cardiogenic shock complicating acute myocardialinfarction undergoing early revascularization were randomized to IABP versus control.Long-term follow
A systematic review of the management and outcomes of perioperative myocardialinfarction after non-cardiac surgery Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated
The long-term and short-term efficacy and safety of transplantation mononuclear cells in patients with myocardialinfarction Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any
What is the timing for release of mature immune cells post myocardialinfarction and its impact on cardiovascular outcomes? Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any
Transradial vs. transfemoral access for percutaneous coronary intervention in ST-elevation myocardialinfarction: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content
Clinical efficacy and safety of percutaneous coronary intervention in patients with acute myocardialinfarction and chronic renal insufficiency: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility
The prognosis and manangment of left ventricular thrombus following acute myocardialinfarction in the contemporary era of primary percutaneous coronary intervention - a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears